The symptomatology of climacteric syndrome: whether associated with the physical factors or psychological disorder in perimenopausal/postmenopausal patients with anxiety-depression disorder
- PMID: 22124532
- PMCID: PMC3325418
- DOI: 10.1007/s00404-011-2151-z
The symptomatology of climacteric syndrome: whether associated with the physical factors or psychological disorder in perimenopausal/postmenopausal patients with anxiety-depression disorder
Abstract
Purpose: To explore whether the symptoms of climacteric syndrome associated with its physical factors or psychological disorder in perimenopausal/postmenopausal patients with anxiety-depression disorder.
Methods: We recruited 78 climacteric patients with anxiety-depression disorder and 72 control participants in perimenopausal/postmenopausal without anxiety-depression disorder for this study. We measured symptoms using the Greene Climacteric Symptom Scale in all cases. We also collected demographic data and tested sexual hormone, blood pressure, bone density, cognitive, estrogen receptor-alpha (ERα) gene polymorphism as physiological factors, using HARS-14 and CHDS assessed psychological disorder degree.
Results: C-MMSE scores as well as Estradiol and progesterone levels in the anxiety-depression disorder group were significantly lower compared to the control group (P < 0.01). In addition, the anxiety-depression disorder group had significantly higher Greene Climacteric Scale scores, as well as somatic symptoms compared to controls (P < 0.01). Moreover, the anxiety, depression and somatic symptoms of the Greene Climacteric Scale were positively correlated with HARS-14 and CHDS scores (P < 0.001) and negatively with estrogen level and C-MMSE scores (P < 0.05) in the anxiety-depression disorder group. Greene Climacteric Scale Symptoms were not significantly correlated with blood pressure, bone density or other factors (P > 0.05). There was no significant change in the allele frequency or the estrogen receptor-alpha gene polymorphisms, between the two groups (P > 0.05); however, the Pp genotype was negatively associated with C-MMSE scores (r = appraises, P = 0.033).
Limitations: The sample size was relatively small.
Conclusions: The symptoms of somatic symptoms in patients with climacteric syndrome and anxiety-depression disorder are associated with the emotional disorder but not with a physical disease. The Pp ERα polymorphism Pvu II is associated with a cognitive decrease.
Figures
Similar articles
-
The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.Int J Pharm Compd. 2013 Jan-Feb;17(1):74-85. Int J Pharm Compd. 2013. PMID: 23627249
-
Effect of symptoms of climacteric syndrome, depression and insomnia on self-rated work ability in peri- and post-menopausal women in non-manual employment.Ann Agric Environ Med. 2019 Dec 19;26(4):600-605. doi: 10.26444/aaem/112838. Epub 2019 Nov 7. Ann Agric Environ Med. 2019. PMID: 31885234
-
Menopausal symptoms and risk factors for cardiovascular disease in postmenopause.Climacteric. 2012 Apr;15(2):157-62. doi: 10.3109/13697137.2011.617852. Epub 2011 Dec 5. Climacteric. 2012. PMID: 22141325
-
Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review.Menopause. 2015 May;22(5):564-78. doi: 10.1097/GME.0000000000000323. Menopause. 2015. PMID: 25203891 Review.
-
Protective and harmful social and psychological factors associated with mood and anxiety disorders in perimenopausal women: A narrative review.Maturitas. 2024 Dec;190:108118. doi: 10.1016/j.maturitas.2024.108118. Epub 2024 Sep 18. Maturitas. 2024. PMID: 39317031 Review.
Cited by
-
Relationship between depression and inflammatory factors and brain-derived neurotrophic factor in patients with perimenopause syndrome.Exp Ther Med. 2018 May;15(5):4436-4440. doi: 10.3892/etm.2018.5985. Epub 2018 Mar 22. Exp Ther Med. 2018. PMID: 29849779 Free PMC article.
-
Polymorphisms of estrogen receptors and risk of depression: therapeutic implications.Drugs. 2012 Sep 10;72(13):1725-38. doi: 10.2165/11635960-000000000-00000. Drugs. 2012. PMID: 22901010 Review.
-
Perception of health, health behaviours and the use of prophylactic examinations in postmenopausal women.BMC Womens Health. 2020 Apr 9;20(1):71. doi: 10.1186/s12905-020-00931-9. BMC Womens Health. 2020. PMID: 32290849 Free PMC article.
-
A Clinical Study of the Effect of Estradiol Valerate on Sleep Disorders, Negative Emotions, and Quality of Life in Perimenopausal Women.Evid Based Complement Alternat Med. 2021 Oct 16;2021:8037459. doi: 10.1155/2021/8037459. eCollection 2021. Evid Based Complement Alternat Med. 2021. Retraction in: Evid Based Complement Alternat Med. 2023 Dec 13;2023:9862610. doi: 10.1155/2023/9862610. PMID: 34697549 Free PMC article. Retracted.
-
Examining the Health-Related Needs of Females during Menopause: A Systematic Review Study.J Menopausal Med. 2023 Apr;29(1):1-20. doi: 10.6118/jmm.22033. J Menopausal Med. 2023. PMID: 37160298 Free PMC article. Review.
References
-
- Soules MR, Sherman S, Parrott E, et al. Executive summary: Stages of Reproductive Aging Workshop (STRAW) Climacteric. 2001;4(4):267–272. - PubMed
-
- Colenda CC, Legault C, Rapp SR, DeBon MW, Hogan P, Wallace R, et al. Psychiatric disorders and cognitive dysfunction among older, postmenopausal women: results from the Women’s Health Initiative Memory Study. Am J Geriatr Psychiatry. 2010;18(2):177–186. doi: 10.1097/JGP.0b013e3181c65864. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous